Wedbush Issues Positive Forecast for Disc Medicine Earnings

Disc Medicine, Inc. (NASDAQ:IRON) – Equities researchers at Wedbush increased their FY2026 earnings per share (EPS) estimates for shares of Disc Medicine in a report released on Tuesday, January 21st. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($3.96) for the year, up from their prior forecast of ($4.19). Wedbush has a “Outperform” rating and a $90.00 price target on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share. Wedbush also issued estimates for Disc Medicine’s FY2027 earnings at $2.64 EPS.

Disc Medicine (NASDAQ:IRON) last issued its earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.15.

IRON has been the subject of a number of other research reports. Morgan Stanley upgraded Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price objective for the company in a research note on Tuesday, November 5th. Jefferies Financial Group began coverage on Disc Medicine in a research note on Wednesday, October 23rd. They set a “buy” rating and a $89.00 price objective for the company. Stifel Nicolaus lifted their price objective on Disc Medicine from $90.00 to $94.00 and gave the company a “buy” rating in a research note on Friday. Cantor Fitzgerald reiterated an “overweight” rating and set a $85.00 price objective on shares of Disc Medicine in a research note on Tuesday, October 15th. Finally, HC Wainwright restated a “buy” rating and issued a $118.00 price target on shares of Disc Medicine in a research note on Tuesday. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Disc Medicine currently has an average rating of “Buy” and a consensus target price of $88.90.

Disc Medicine Stock Performance

NASDAQ IRON opened at $57.45 on Thursday. The stock has a 50-day simple moving average of $62.62 and a two-hundred day simple moving average of $53.79. The firm has a market capitalization of $1.71 billion, a P/E ratio of -14.43 and a beta of 0.75. Disc Medicine has a fifty-two week low of $25.60 and a fifty-two week high of $77.60.

Insider Buying and Selling

In related news, Director William Richard White sold 7,136 shares of Disc Medicine stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $58.61, for a total value of $418,240.96. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO John D. Quisel sold 19,820 shares of Disc Medicine stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $63.14, for a total value of $1,251,434.80. Following the completion of the sale, the chief executive officer now owns 72,065 shares in the company, valued at approximately $4,550,184.10. The trade was a 21.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 85,758 shares of company stock worth $5,400,990. Insiders own 4.24% of the company’s stock.

Institutional Investors Weigh In On Disc Medicine

Institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP boosted its holdings in shares of Disc Medicine by 4.8% during the 3rd quarter. Wellington Management Group LLP now owns 1,840,226 shares of the company’s stock worth $90,429,000 after purchasing an additional 83,731 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its holdings in shares of Disc Medicine by 123.5% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 1,754,834 shares of the company’s stock worth $79,090,000 after purchasing an additional 969,834 shares during the last quarter. Deerfield Management Company L.P. Series C boosted its holdings in shares of Disc Medicine by 53.8% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,023,265 shares of the company’s stock worth $46,119,000 after purchasing an additional 357,730 shares during the last quarter. State Street Corp boosted its holdings in shares of Disc Medicine by 39.7% during the 3rd quarter. State Street Corp now owns 827,910 shares of the company’s stock worth $40,683,000 after purchasing an additional 235,115 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in shares of Disc Medicine during the 2nd quarter worth approximately $34,318,000. 83.70% of the stock is currently owned by institutional investors and hedge funds.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.